photochlor
Small moleculeexperimental
2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a (HPPH), a chlorin-based photosensitize, is used in photodynamic therapy. It has been shown the therapeutic potential of HPPH in phase II clinical trials for the treatment of esophageal cancer. Besides, HPPH participated in clinical trials in treating patients with advanced non-small cell lung cancer that blocks the air passages. However, these studies were terminated. — NCATS
Clinical trial activity
16 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 1997 (NCT00060268)
Timeline
Indications
Studied for
- Adenocarcinoma of Lung · Phase 1
- Barrett Esophagus · Phase 1
- Basal Cell Carcinoma · Phase 1
- Bronchopulmonary Dysplasia · Phase 1
- Carcinoma, Adenoid Cystic · Phase 1
- Carcinoma, Mucoepidermoid · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Squamous Cell · Phase 2
- Carcinoma, Verrucous · Phase 2
- Developmental Dysplasia of the Hip · Phase 1
- Esophageal Neoplasms · Phase 2
- Graft vs Host Disease · Phase 1
- Granuloma · Phase 1
- Head and Neck Neoplasms · Phase 1
- Lung Neoplasms · Phase 2
- Melanoma · Phase 1
- Nasopharyngeal Neoplasms · Phase 1
- Neoplasm Metastasis · Phase 1
- Neoplasms · Phase 1
- Neuroblastoma · Phase 1
- Oropharyngeal Neoplasms · Phase 1
- Papilloma, Inverted · Phase 1
- Precancerous Conditions · Phase 2
- Salivary Gland Neoplasms · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Thyroid Neoplasms · Phase 1
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
CCCCCCOC(C)C1=C(C)C2=CC3=NC([C@@H](CCC(O)=O)[C@@H]3C)=C4CC(=O)C5=C4NC(C=C6N=C(C=C1N2)C(C)=C6CC)=C5C- Mol. weight
- 636.8228 g/mol
Oral
No
Parenteral
No
Topical
No
Sources
Also known as
- 2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a
- hpph
- hpph
- hpph
- photochlor
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03090412 | Phase 2 | Mar 30, 2017 | National Cancer Institute (NCI), State University of New York, Buffalo |
| NCT02119728 | Phase 2 | Apr 17, 2014 | National Cancer Institute (NCI), State University of New York, Buffalo |
| NCT01140178 | Phase 1 | Jun 8, 2010 | National Cancer Institute (NCI), State University of New York, Buffalo |
| NCT00670397 | Phase 1 | Jun 1, 2010 | State University of New York, Buffalo |
| NCT01035437 | N/A | Dec 1, 2009 | State University of New York, Buffalo |
| NCT00675233 | Phase 1 | Apr 25, 2008 | State University of New York, Buffalo |
| NCT00528775 | Phase 2 | Aug 1, 2007 | National Cancer Institute (NCI), State University of New York, Buffalo |
| NCT00470496 | Phase 1 | Oct 19, 2006 | National Cancer Institute (NCI), State University of New York, Buffalo |
| NCT00526461 | Phase 1 | Feb 1, 2004 | National Cancer Institute (NCI), State University of New York, Buffalo |
| NCT00281736 | Phase 2 | Feb 1, 2004 | State University of New York, Buffalo |
| NCT01668823 | Phase 1 | Feb 1, 2004 | National Cancer Institute (NCI), State University of New York, Buffalo |
| NCT01238042 | Phase 1 | Mar 1, 2003 | State University of New York, Buffalo |
| NCT00025571 | Phase 1 | Jun 1, 2001 | State University of New York, Buffalo |
| NCT01236443 | Phase 1 | Aug 1, 2000 | State University of New York, Buffalo |
| NCT00017485 | Phase 1 | Jan 1, 2000 | National Cancer Institute (NCI), State University of New York, Buffalo |
| NCT00060268 | Phase 1/Phase 2 (Phase 2) | Jan 1, 1997 | State University of New York, Buffalo |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| State University of New York, Buffalo | Academic/Hospital | 16 | 16 | 3 | 1997 |
| National Cancer Institute (NCI) | Government | 8 | 0 | 2 | 2000 |
2 organizations
Page 1 / 1